Author:
Wilkinson Bethanie,Patel Kinjal S.,Smith Katherine,Walker Robert,Wang Chengbin,Greene Ann M.,Smith Gale,Smith Emily R.,Gurwith Marc,Chen Robert T.
Funder
U.S. Food and Drug Administration
U.S. Department of Defense
National Institute of Allergy and Infectious Diseases
U.S. Department of Health and Human Services
Biomedical Advanced Research and Development Authority
Coalition for Epidemic Preparedness Innovations
National Institutes of Health
Centers for Disease Control and Prevention
Subject
Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine
Reference69 articles.
1. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico;Dunkle;NEJM,2022
2. Safety and efficacy of NVX-COV2373 Covid-19 vaccine;Heath;NEJM,2021
3. Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine;Keech;NEJM,2020
4. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial;Mallory;Lancet Infect Dis,2022
5. EMA. Summary of Product Characteristics (SmPC) Nuvaxovid. [Online]. Available: https://www.ema.europa.eu/en/documents/product-information/nuvaxovid-epar-product-information_en.pdf. [Accessed 28 September 2022].